TABLE 1.

Characteristics of HIV-1-positive study participants^a

Participant ID	Age	Sex	Ethnicity	CD4 count (cells/μl)	ART regimen	ART start date (yr)
2147	59	Male	Asian	597	RPV/TDF/FTC	1995
3162	54	Male	White	734	RTV, DRV, ABC/TCV/3TC	2000
3068	62	Male	White	452	ABC/3TC, ETV, RGV	2000
2256	60	Male	White	315	EFV/TDF/FTC, RGV	2001
1128	66	Male	African American	480	3TC, EFV, RGV	2008
2013	68	Male	White	715	ABC/TCV/3TC	1996
2511	48	Male	White	334	EFV/TDF/FTC, RGV	2010
2046	52	Male	Pacific Islander	580	ECV, EFV/TDF/FTC	1995
1036	48	Male	African American	410	EGV/TAF/FTC/COBI	2008
2402	40	Male	African American	765	RTV, DRV, RPV/TDF/FTC	2006
1602	39	Male	Native American	459	RPV/TDF/FTC	2011
2643	55	Male	White	322	ABC/TCV/3TC	2017
1695	39	Female	Mixed	556	FTC/TDF, ATV, RTV	2010
2161	68	Male	White	687	3TC, RTV, DRV, TCV	2005
1079	66	Male	Latino	481	ETV, FTC/TAF	2004
2135	60	Male	White	328	RPV/TAF/FTC, RGV	2006
2168	57	Male	African American	272	ABC/TCV/3TC	2000
2461	63	Male	White	496	ABC/TCV/3TC	1999
1380	60	Female	African American	760	RPV/TAF/FTC	2011
2658	39	Male	Mixed	614	EFV/TDF/FTC	2011
2722	56	Male	Latino	987	FTC/TAF	2016
2253	67	Male	White	643	ABC/TCV/3TC	2006
2756	45	Male	Mixed	799	ABC/3TC, RTV, DRV	2008

^aRPV, rilpivirine; TDF, tenofovir; FTC, emtricitabine; DRV, darunavir; ABC, abacavir; TCV, dolutegravir; 3TC, lamivudine; ETV, etravirine; RGV, raltegravir; EFV, efavirenz; ECV, entecavir; EGV, elvitegravir; TAF, tenofovir alafenamide; COBI, cobicistat; ATV, atazanavir; RTV, ritanovir.